Present status and future perspectives of heart transplantation

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1097-1110

  Toyoda, Yoshiya ^a   Sloane Guy, T ^a   Kashem, Abul ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endstage heart failure; Heart transplantation; Organ procurement; Transplant center; Ventricular assist devices

Indexed keywords

ADRENALIN; ALEMTUZUMAB; ARGIPRESSIN; ATROPINE; AZATHIOPRINE; BASILIXIMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIGOXIN; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HLA ANTIBODY; HLA ANTIGEN; INSULIN; LIOTHYRONINE; LYMPHOCYTE ANTIBODY; MANNITOL; METHYLPREDNISOLONE; MILRINONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; OKT 3; PROSTACYCLIN; PROSTAGLANDIN E1; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ACUTE VASCULAR REJECTION; ALLOGRAFT; BACTERIAL INFECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CONTINUOUS INFUSION; DEATH; DONOR SELECTION; EVALUATION; FOLLOW UP; GOVERNMENT; GRAFT FAILURE; GRAFT RECIPIENT; HEART ARRHYTHMIA; HEART TRANSPLANTATION; HEMODYNAMICS; HLA MATCHING; HUMAN; HYPERACUTE GRAFT REJECTION; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LYMPHOMA; MYCOSIS; PROTOZOAL INFECTION; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL GRAFT DYSFUNCTION; RESPIRATORY CARE; REVIEW; VIRUS INFECTION;

BACTERIAL INFECTIONS; DONOR SELECTION; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME; UNITED STATES; VIRUS DISEASES;

EID: 84876759612     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0296     Document Type: Review

References (103)

1. Heart Disease and Stroke Statistics: 2013 Update. A report from the American Heart Association. Circulation 2013; 127: e6-e245.
2. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2009; 2: 407-413.
3. Hunt SA. Taking heart: Cardiac transplantation past, present, and future. N Engl J Med 2006; 355: 231-235.
4. Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol 2008; 52: 587-598.
5. The Registry of the International Society for Heart and Lung Transplantation. Introduction to the 2012 annual reports: New leadership, same vision. J Heart Lung Transplant 2012; 31: 1045-1095.
6. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
7. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-896.
8. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuousflow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
9. Organ Procurement and Transplantation Network. By Laws, December 13, 2012.
10. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients. Annual Data Report: heart. 2011.
11. Medicare Program. Hospital Conditions of Participation (CoP): Requirements for approval and re-approval of transplant centers to perform organ transplants; final rule. Fed Reg 2007; 72: 15198.
12. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, et al. Selection and treatment of candidates for heart transplantation: A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995; 92: 3593-3612.
13. Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw LJ, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996; 27: 345-352.
14. Florea VG, Henein MY, Anker SD, Francis DP, Chambers JS, Ponikowski P, et al. Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. Eur Heart J 2000; 21: 146-153.
15. Boyle A, Colvin-Adams M. Recipient selection and management. Semin Thorac Cardiovasc Surg 2004; 16: 358-363.
16. Deng MC. Cardiac transplantation. Heart 2002; 87: 177-184.
17. Cochran RP, Starkey TD, Panos AL, Kunzelman KS. Ambulatory intraaortic balloon pump use as bridge to heart transplant. Ann Thorac Surg 2002; 74: 746-751.
18. Fang JC. Rise of the machines: Left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med 2009; 361: 2282-2285.
19. Zachary AA, Montgomery RA, Simpkins CE, Warren D, Leffell MS. Impact of persistent, low levels of donor specific antibody on renal transplants. Am J Transplant 2005; 5: 245.
20. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009; 70: 496-501.
21. Tambur AR, Leventhal J, Kaufman DB, Friedewald J, Miller J, Abecassis MM. Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: The Northwestern University experience. Transplantation 2008; 86: 1052-1059.
22. Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K, et al. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: The utility of luminex. J Heart Lung Transplant 2009; 28: 123-129.
23. Kerman RH. Understanding the sensitized patient. Heart Fail Clin 2007; 3: 1-9.
24. Lavee J, Kormos RL, Duquesnoy RJ, Zerbe TR, Armitage JM, Vanek M, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991; 10: 921-929.
25. Itescu S, Schuster M, Burke E, Ankersmit J, Kocher A, Deng M, et al. Immunobiologic consequences of assist devices. Cardiol Clin 2003; 21: 119-133.
26. Terasaki P, Mickey MR, Iwaki Y, Cicciarelli J, Cecka M, Cook D, et al. Long-term survival of kidney grafts. Transplant Proc 1989; 21: 615-617.
27. Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 1985; 40: 240-243.
28. Zangwill SD, Ellis TM, Zlotocha J, Jaquiss RD, Tweddell JS, Mussatto KA, et al. The virtual cross match: A screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006; 10: 38-41.
29. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual cross match. Pediatr Transplant 2007; 11: 650-654.
30. Appel JZ III, Hartwig MG, Cantu E III, Palmer SM, Reinsmoen NL, Davis RD. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81: 1049-1057.
31. Vaidya S. Clinical importance of antihuman leukocyte antigenspecific antibody concentration in performing calculated panel reactive antibody and virtual cross matches. Transplantation 2008; 85: 1046-1050.
32. Vaidya S, Partlow D, Susskind B, Noor M, Barnes T, Gugliuzza K. Prediction of cross match outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006; 82: 1524-1528.
33. Zachary AA, Montgomery RA, Leffell MS. Defining unacceptable HLA antigens. Curr Opin Organ Transplant 2008; 13: 405-410.
34. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigenspecific antibodies. Hum Immunol 2008; 69: 591-604.
35. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, Luminex binding antibodies: A new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809-2815.
36. Worsley CM, Mayne ES, Suchard MS. Luminex-based virtual crossmatching for renal transplantation in South Africa. S Afr Med J 2012; 102: 40-43.
37. Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD, D'Alessandro A, Dec GW, et al. Consensus conference report. Maximizing use of organs recovered from the cadaver donor: Cardiac recommendations, March 28-29, 2001, Crystal City, VA. Circulation 2002; 106: 836-841.
38. Hsu RB, Chu SH, Chien CY, Chou NK, Chen YS, Ko WJ, et al. Heart transplantation with marginal recipients and donors. J Formos Med Assoc 1999; 98: 663-667.
39. Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, et al; UCLA Heart Tranplant Group. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg 2003; 125: 49-59.
40. Freimark D, Aleksic I, Trento A, Takkenberg JJ, Valenza M, Admon D, et al. Hearts from donors with chronic alcohol use: A possible risk factor for death after heart transplantation. J Heart Lung Transplant 1996; 15: 150-159.
41. Freimark D, Czer LS, Admon D, Aleksic I, Valenza M, Barath P, et al. Donors with a history of cocaine use: Effect on survival and rejection frequency after heart transplantation. J Heart Lung Transplant 1994; 13: 1138-1144.
42. Jarcho J, Naftel DC, Shroyer JK, Kirklin JK, Bourge RC, Barr ML, et al. Influence of HLA mismatch on rejection after heart transplantation: A multi-institutional study. J Heart Lung Transplant 1994; 13: 583-595.
43. Urelsky BF. Physiology of the transplanted heart. Cardiovasc Clin 1990; 20: 23-56.
44. Tischler MD, Lee RT, Plappert T, Mudge GH, St John Sutton M, Parker JD. Serial assessment of left ventricular function and mass after orthotopic heart transplantation: A four-year longitudinal study. J Am Coll Cardiol 1992; 19: 60-66.
45. Kirklin JK, Naftel DC, Bourge RC, McGiffin DC, Hill JA, Rodeheffer RJ, et al. Evolving trends in risk profiles and causes of death after heart transplantation: A ten-year multi-institutional study. J Thorac Cardiovasc Surg 2003; 125: 881-890.
46. Minev PA, El-Banayosy A, Minami K, Körtke H, Kizner L, Körfner R. Differential indication for mechanical circulatory support following heart transplantation. Intensive Care Med 2001; 27: 1321-1327.
47. Srivastava R, Keck BM, Bennett LE, Hosenpud JD. The results of cardiac retransplantation: An analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation 2000; 70: 606-612.
48. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation: A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant 1993; 12: 179-184.
49. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: Effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 1995; 14: 436-443.
50. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001; 72: 638-641.
51. Patel VS, Lim M, Massin EK, Jonsyn GP, Ates P, Abou-Awdi NL, et al. Sudden cardiac death in cardiac transplant recipients. Circulation 1996; 94: II-273-II-277.
52. Kwak YL, Oh YJ, Bang SO, Lee JH, Jeong SM, Hong YW. Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary artery bypass graft surgery. J Int Med Res 2004; 32: 342-350.
53. Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth official report 2002. J Heart Lung Transplant 2002; 21: 950-970.
54. John R, Rajasinghe HA, Chen JM, Weinberg AD, Sinha P, Mancini DM, et al. Long-term outcomes after cardiac transplantation: An experience based on different eras of immunosuppressive therapy. Ann Thorac Surg 2001; 72: 440-449.
55. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult heart transplant report - 2010. J Heart Lung Transplant 2010; 29: 1089-1103.
56. Rosenberg PB, Vriesendorp AE, Drazner MH, Dries DL, Kaiser PA, Hynan LS, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24: 1327-1331.
57. Yamani MH, Taylor DO, Czerr J, Haoire C, Kring R, Zhou L, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: Results of a prospective, randomized, controlled study. Clin Transplant 2008; 22: 76-81.
58. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78: 779-781.
59. Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gómez-Sánchez MA, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006; 81: 1542-1548.
60. Caillat-Zucman S, Blumenfeld N, Legendre C, Noel LH, Bach JF, Kreis H, et al. The OKT3 immunosuppressive effect: In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990; 49: 156-160.
61. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995; 17: 615-620.
62. Teuteberg JJ, Shullo MA, Zomak R, Toyoda Y, McNamara DM, Bermudez C, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: One-year outcomes. Am J Transplant 2010; 10: 382-388.
63. Taylor DO. Cardiac transplantation: Drug regimens for the 21st century. Ann Thorac Surg 2003; 75: S72-S78.
64. Trento A, Hardesty RL, Griffith BP, Zerbe T, Kormos RL, Bahnson HT. Role of the antibody to vascular endothelial cells in hyperacute rejection in patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg 1988; 95: 37-41.
65. Forbes RDC, Guttman RD. Evidence for complement-induced endothelial injury in vivo: A comparative ultrastructural tracer study in a controlled model of hyperacute rate cardiac allograft rejection. Am J Pathol 1982; 106: 378-387.
66. Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, et al. Pretransplantation risk factors for acute rejection after heart transplantation: A multi-institutional study: The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12: 355-366.
67. Miller LW. Treatment of cardiac allograft rejection with intervenous corticosteriods. J Heart Transplant 1990; 9: 283-287.
68. Cunningham KS, Veinot JP, Butany J. An approach to endomyocardial biopsy interpretation. J Clin Pathol 2006; 59: 121-129.
69. Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Lung Transplant 1990; 9: 587-593.
70. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
71. Michler RE, Smith CR, Drusin RE, Reison DS, Hickey TJ, Lamb J, et al. Reversal of cardiac transplant rejection without massive immunosuppression. Circulation 1986; 74: III-68-III-71.
72. Lloveras JJ, Escourrou G, Delisle MG, Fournial G, Cerene A, Bassanetti I, et al. Evolution of untreated mild rejection in heart transplant recipients. J Heart Lung Transplant 1992; 11: 751-756.
73. Winters GL, Loh E, Schoen FJ. Natural history of focal moderate cardiac allograft rejection: Is treatment warranted? Circulation 1995; 91: 1975-1980.
74. Park MH, Starling RC, Ratliff NB, McCarthy PM, Smedira NS, Pelegrin D, et al. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant 1999; 18: 1224-1227.
75. Stoica SC, Cafferty F, Pauriah M, Taylor CJ, Sharples LD, Wallwork J, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25: 420-425.
76. Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: A study in 81 consecutive patients. J Heart Lung Transplant 1995; 14: 151-162.
77. Olsen SL, Wagoner LE, Hammond EH, Taylor DO, Yowell RL, Ensley RD, et al. Vascular rejection in heart transplantation: Clinical correlation, treatment options, and future considerations. J Heart Lung Transplant 1993; 12: S135-S142.
78. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O'Connell JB, et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 1992; 11: S111-S119.
79. Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC, Jarcho J, et al. Infection after heart transplantation: A multi-institutional study. J Heart Lung Transplant 1994; 13: 381-392.
80. Pereira BJG, Milford EL, Kirkman RL. Transmission of hepatitis C virus organ transplantation. N Engl J Med 1991; 325: 454-460.
81. Eastlund T. Infectious disease transmission through cell, tissue, and organ transplantation: Reducing the risk through donor selection. Cell Transplant 1995; 4: 455-477.
82. Rubin RH. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000; 19: 731-735.
83. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182-1186.
84. Egan JJ, Barber L, Lomax J, Fox A, Yonan N, Rahman AN, et al. Detection of human cytomegalovirus antigenaemia: A rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995; 50: 9-13.
85. Montoya JG, Chaparro SV, Celis D, Cortes JA, Leung AN, Robbins RC, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37: S281-S292.
86. Cardenal R, Medrano FJ, Varela JM, Ordonez A, Regordan C, Rincon M, et al. Pneumocystis carinii pneumonia in heart transplant recipients. Eur J Cardiothorac Surg 2001; 20: 799-802.
87. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Deng MC, Keck BM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005; 24: 945-955.
88. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Seventeenth official report - 2000. J Heart Lung Transplant 2000; 19: 909-931.
89. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11: S38-S44.
90. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK 3rd, Bpoehmer JP, Brozena SC, et al. Heart transplant coronary artery disease detected by coronary angiography: A multi-institutional study of preoperative donor and recipient risk factors: Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17: 744-753.
91. Day JD, Rayburn BK, Gaudin PB, Baldwin WM 3rd, Lowenstein CJ, Kasper EK, et al. Cardiac allograft vasculopathy: The central pathogenic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14: S142-S149.
92. Hollenberg SM, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091-3096.
93. Bocksch W, Wellnhofer E, Schartl M, Dreysse S, Klimek W, Franke R, et al. Reproducibility of serial intravascular ultrasound measurements in patients with angiographically silent coronary artery disease after heart transplantation. Coron Artery Dis 2000; 11: 555-562.
94. Smart FW, Ballantyne CM, Cocanougher B, Farmer JA, Sekela ME, Noon GP, et al. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol 1991; 67: 243-247.
95. Kass M, Haddad H. Cardiac allograft vasculopathy: Pathology, prevention and treatment. Curr Opin Cardiol 2006; 21: 132-137.
96. Redonnet M, Tron C, Koning R, Bouchart F, Cribier A, Soyer R, et al. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. Transplant Proc 2000; 32: 463-465.
97. Mehra MR, Ventura HO, Smart FW, Stapleton DD. Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: From bench to bedside. J Heart Lung Transplant 1995; 14: S246-S249.
98. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
99. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
100. Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D. Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors. Transplant Proc 2005; 37: 4S-17S.
101. Sivathasan C. Experience with cyclosporine in heart transplantation. Transplant Proc 2004; 36: 346S-348S.
102. Brozena SC, Johnson MR, Ventura H, Hobbs R, Miller L, Olivari MT, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation: Results of a prospective, randomized multicenter trail. J Am Coll Cardiol 1996; 27: 1707-1712.
103. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336-345.